# Amoy Diagnostics Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amoy-diagnostics-co

- Industry: Medical Devices & Equipment
- Headquarters: Xiamen, China
- Website: www.amoydiagnostics.com
- Total disclosed funding: $4.4M
- Latest round: Series B (Sep 2, 2013)
- Investors on record: 1

## About

Amoy Diagnostics Co., Ltd. specializes in innovative diagnostic solutions to enhance precision oncology, offering advanced technologies for cancer diagnosis to healthcare providers and pharmaceutical companies.Founded in 2008 in Xiamen, China, Amoy Diagnostics focuses on developing diagnostic solutions for oncology. The company raised CNY 277.2 million in its IPO on July 20, 2017, marking a significant milestone in its operational strategy. The founder's history is not documented.AmoyDx provides innovative diagnostic technologies tailored for oncology, including HANDLE® Technology, which simplifies next-generation sequencing testing, and ADx-ARMS® Technology, enhancing sensitivity to 0.2%. Its clientele includes hospitals and pharmaceutical companies across Europe and Asia, particularly in Japan and China, aiming to address complex cancer diagnostic challenges.In the most recent year, 2021, AmoyDx reported revenue of CNY 142,141,155.5 and an EBITDA of CNY 44,901,661.6. The company generates revenue through a mix of B2B and direct-to-consumer sales, primarily from its core products offered to healthcare providers and laboratories.Amoy Diagnostics plans to leverage the proceeds from its IPO to enhance product development and market penetration. The company is focusing on expanding its product line and anticipates launching new diagnostic tools in the upcoming years. Additionally, it aims to enter new markets, specifically targeting opportunities in North America and further into Europe by 2025.

## Funding rounds

- Series B, Sep 2, 2013, $4.4M — Qiming Venture Partners

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B